Vaccines have been a part of medical practice for more than 200 years, since Edward Jenner developed an inoculation for smallpox in 1796. Vaccination has been used routinely for decades in the US, with a typical American receiving his or her first vaccination at 1 week of age to protect against a variety of childhood illnesses. This once-novel treatment modality is now a common way of building up the immune system to fight infection. Vaccines have been exceptionally effective against smallpox, measles, chickenpox, and polio. They are among the safest and most cost-effective preventative agents.
The antibody (immune) response that cancer vaccines stimulate is the principal means by which they may limit or prevent carcinogenesis. Though cancer is not considered an "infection," we know that some cancers are caused by infectious agents. For example, human papillomavirus (HPV) causes cervical and anogenital carcinomas, and hepatitis B virus (HBV) is associated with hepatocellular carcinoma. Many clinical trials are under way to test vaccines as potential preventive and therapeutic agents for a variety of cancers. In particular, scientists from the National Cancer Institute are studying use of cytokines--endogenous small secreted proteins which mediate and regulate immune function, inflammation, and hematopoiesis--to increase the response of the immune system to experimental vaccines. Vaccinations for various types of common cancers are likely to be cost-effective if paired with effective cancer screening practices.
The benefit of cancer treatment vaccines lies in their ability to "boost" the immune system response to cancer cells, which is generally low because tumors are not sufficiently different from normal cells to be recognized as foreign; cancer cells also may shed antigens or exert other immune-modulating effects that make them less vulnerable to attack by the body's immune system.
This article describes the state of the science of cancer vaccines, which are being developed both for primary prevention in healthy individuals (by stimulating the immune system to attack cancer-causing viruses, thereby preventing the viral infection) and as therapeutic agents for people already diagnosed with cancer, with therapeutic vaccines stimulating the body's immune system to target cancer calls without destroying healthy cells. Recommendations are made regarding roles of oncology nurses in this promising new avenue of cancer care.
Immune System Basics
The human immune system comprises several types of cells formed in the bone marrow that circulate through the lymphatic system. Some immune cells have general or nonspecific functions. Others, such as T lymphocytes (T cells) and B lymphocytes (B cells), have specific functions. They recognize and are activated by specific antigens. B lymphocytes produce antibodies directed towards specific antigens, and cytotoxic T cells identify and kill cells containing the recognized antigen. Helper T cells release cytokines, including interferons and interleukins, which enhance immune activity at the site of the foreign-cell invasion by stimulating T cells to attack and B cells to produce more antibody. Cancer immunologists have high interest in these cell types.
Eliciting the Immune Response
A vaccine is a preparation, usually administered subcutaneously, that creates a state of protection against a disease. Vaccines are created using carbohydrate and whole, or parts of, protein molecules from viruses or cells from bacteria, humans, or other animals. DNA or RNA may also be used to make vaccines. The molecules may contain a single antigen or several antigens.
The immune system responds by making antibodies against specific antigens present in the vaccine. Ideally, these antibodies are able to attack and destroy any substance identified by the body as foreign. Later, if the same substance is introduced anew, the circulating antibodies of the "vaccine-educated" immune system will recognize and destroy the foreign material. Some vaccines are long-lasting and protect an individual for years or even a lifetime. Others have limited longevity and must be enhanced by periodic revaccination.
Advances in molecular biology and immunology have enhanced the opportunities to develop new vaccines. As new vaccines are developed and tested, they also are subject to review by a cooperative infrastructure of organizations convened by the National Institute of Allergy and Infectious Diseases. This consortium includes the National Cooperative Vaccine Development Groups, the HIV Vaccine Trials Network, the AIDS Vaccine Evaluation Group, and the National Cancer Institute of the National Institutes of Health.
Preventive Cancer Vaccines
A cancer vaccine is generally considered an immunotherapy and is only preventive if it is administered before cancerous cells develop. The HPV and HBV vaccines, which are the only vaccines approved for cancer prevention, work by blocking infection with the causative agent, thereby preventing cancer in the vulnerable organs (cervix and liver, respectively). Other malignancies besides cervical and hepatic cancer that are associated with viruses include Burkitt's lymphoma and gastroadenocarcinoma, associated with Epstein Barr virus (EBV) type 1; nasopharyngeal carcinoma, associated with EBV type II; adult T cell leukemia, associated with HTLV-1; and Kaposi's sarcoma, associated with HHV-8. Currently, no vaccines exist against the antigens associated with these viral agents.
Owing to factors inherent in the carcinogenesis process, cancer immunotherapy is easier when a causative agent can be targeted, as with cervical and liver cancers. HPV is the primary cause of cervical cancer. Early trials of the HPV vaccine (n = 1,500 young women) showed it to be 100% effective in preventing persistent HPV infection and low-grade cervical cytological abnormalities attributable to HPV 16 and HPV 18 strains of the virus.[7,8] These trials resulted in FDA approval in June 2006 of a quadrivalent HPV vaccine (against HPV types 6,11,16, and 18) for females aged 9 to 36 years (Gardasil).
Importantly, vaccination is only one approach toward reducing cancer risk. Other factors need to be considered. In terms of HPV infection, for example, there are 15 strains of HPV associated with cancer, 90% of HPV infections clear spontaneously within 2 years, the median age of cervical cancer diagnosis is 48 years, 60% of men are infected with HPV, and the HPV vaccine is not approved for males. There has also been controversy surrounding efforts to make vaccination of school-age girls mandatory. (See Table 1.)
1. The Albert B. Sabin Vaccine Institute. Vaccine Science. Washington, DC, 2007. Available at: http://www.sabin.org/vaccine_science/index.html. Accessed August 28, 2007.
2. Morse M, Clay TM, Lyerly HK: Biology of the cancer vaccine immune response, in Morse MA, Clay TM, Lyerly HK (eds): Handbook of Cancer Vaccines, pp 3–10. Totowa, New Jersey, Humana Press, 2004.
3. Collins Y, Einstein MH, Gostout, BS, et al: Cervical cancer prevention in the era of prophylactic vaccines: A preview for gynecologic oncologists. Gynecol Oncol 102:552–562, 2006.
4. Brisson M, Van de Velde N, De Wals P, et al: The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25(29):5399–5408, 2007.
5. Biswas S, Guix M, Rinehart C, et al: Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 117(5):1305–1313, 2007.
6. Parmely MM: Immunology. New York, Lange Medical Books, McGraw Hill, 2006.
7. Garland SM, Hernandez-Avila M, Wheeler CM, et al: Quadrivalent vaccine against human papillomavirus to prevent anogenital disease. N Engl J Med 356:1928–1943, 2007.
8. Lowy DR, Schiller JT: Prophylactic human papillomavirus vaccines. J Clin Invest 116(5):1167–1173, 2006.
9. Savage L: Proposed HPV vaccine mandates rile health experts across the country. J Natl Cancer Inst 99(9):665–666, 2006.
10. Hoos A, Parmiani G, Hege K, et al: A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30(1):1–15, 2007.
11. Acres B, Limacher J, Bonnefoy J: Discovery and development of therapeutic cancer vaccines. Curr Opin Drug Discov Devel 102:185–192, 2007.
12. Keilholz U, Weber J, Finke J, et al: Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the society for biological therapy. J Immunother 25:97–138, 2002.
13. Ribas A, Butterfield LH, Glaspy JA, et al: Current developments in cancer vaccine and cellular immunotherapy. J Clin Oncol 21:2415–2432, 2003.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment of solid tumors. J Natl Cancer Inst 92:205–216, 2000.
15. Thompson T: Cancer vaccines: Advances give hope for future therapy. Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 2007.
16. Leonhartsberger N, Ramoner R, Putz T, et al: Antigen-independent immune responses after dendritic cell vaccination. Cancer Immunol 56(6):897–903, 2007.
17. Wan YY, Flavell RA: The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol Rev 212:114–113, 2006.
18. Chabalgoity JA, Baz A, Rial A, et al: The relevance of cytokines for development of protective immunity and rational design of vaccines. Cytok Growth Factor Rev 18(1-2):195–207, 2007.
19. Finke JH, Bukowski RM (eds): Cancer Immunotherapy at the Crossroads: How tumors evade immunity and what can be done. Totowa, New Jersey, Humana Press, 2004.
20. Ullenhag GJ, Spendlove I, Watson NF, et al: A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clinical Cancer Res 12(24):7389–7396, 2006.
21. Harrop R, Drury N, Shingler W, et al: Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 13(15 Pt 1):4487–4494, 2007.
22. Amato RJ: 5T4-modified vaccine ankara: Progress in tumor-associated antigen-based immunotherapy. Expert Opin Biol Ther 7(9):1463–1469, 2007.
23. Park JW, Melisko ME, Esserman LJ, et al: Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen lapuleucel-T: Results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol 25(24):3680–3687, 2007.
24. Czerniecki BJ, Koski GK, Koldovsky U, et al: Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 67(4):1842–1852, 2007.
25. Hueman MT, Stojadinovic A, Storrer CE, et al: Analysis of naive and memory CD4 ad CD8 T cell populations in breast cancer patients receiving HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol Immunother 56(2):135–136, 2007.
26. Dendreon Corporation. Dendreon receives complete response letter from FDA for Provenge biologics license application (news release). Seattle, Washington, May 9, 2007. Available at: http://investor.dendreon.com/ReleaseDetail.cfm?ReleaseID=241649. Accessed September 4, 2007.
27. Wynia MK: Public health, public trust and lobbying. Am J Bioethics 7(6):4–7, 2007.
28. Burd EM: Human papillomavirus and cervical cancer. Clin Microbiol Rev 16:1–17, 2003.
29. CancerCare, Inc.. The future role of cancer vaccines. New York, CancerCare, Inc., 2007. Available at: http://www.cancercare.org/pdf/booklets/ccc_vaccines.pdf. Accessed on September 4, 2007.
30. Silk AW, Finn OJ: Cancer vaccines: A promising cancer therapy against all odds. Future Oncol 3(3):299–306, 2007.
31. Villa LL, Costa RLR, Petta CA, et al: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95(11):1459–1466, 2006.
32. Tomson TT, Roden RB, Wu TC: Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr Opin Invest Drugs 5: 1247–1261, 2004.
33. Villa LL, Ault KA, Giuliano AR, et al: Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24(27-28):5571–5583, 2006.
34. Chang DZ: The current status of vaccine development in colorectal cancer. Clin Adv Hematol Oncol 5(2):109–111, 2007.
35. Zhang X, Moche JA, Farber D, et al: Vaccine-based approaches to squamous cell carcinoma of the head and neck. Oral Dis 13:17–22, 2007.
36. Liu CJ, Kao JH: Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J Chinese Med Assoc 70(4): 141–145, 2007.
37. Zhang HM, Zhang LW, Liu WC, et al: Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma. Cytotherapy 8(6):580–588, 2006.
38. Hirschowitz AE, Heistand DM, Yannelli JR: Vaccines for lung cancer. J Thorac Oncol 1(1):93–104, 2006.
39. Lee ST, Jiang YF, Park KU, et al: BiovaxID: A personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. Expert Opin Biol Ther 7(1):113-122, 2007.
40. Woloszynska-Read A: Epigenetic regulation of NY-ESO in ovarian cancer. Poster presentation at the 2007 centennial meeting of the American Association for Cancer Research, Los Angeles, California, April 14–18, 2007.
41. National Cancer Institute: NCI Protocol # 06-C-0200. Phase I study for patients with advanced renal cell carcinoma or malignant melanoma. Bethesda, Maryland, 2007.
42. National Cancer Institute: NCI Protocol # 06-C-0069. Phase II study for patients with melanoma: Evaluation of the impact of adjuvants accompanying peptide immunization in high risk melanoma. Bethesda, Maryland, 2007.
43. National Cancer Institute: Cancer vaccine fact sheet. Bethesda, Maryland, 2006. Available at: http://www.cancer.gov/cancertopics/factsheet/cancervaccine. Accessed on September 4, 2007.
44. Gostin LO, DeAngelis CD: Mandatory HPV vaccination. JAMA 297(17):1921–1923, 2007.